Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of temperature-sensitive (TS) p53 mutations and potassium antimony tartrate (PAT)-treatable p53 mutations in mammalian U937 (free of endogenous p53) cells using a systematic p53 mutation library

ABSTRACT: Identification of temperature-sensitive (TS) p53 mutations and potassium antimony tartrate (PAT)-treatable p53 mutations in mammalian U937 (free of endogenous p53) cells using a systematic p53 mutation library

PROVIDER: PRJNA729500 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14513489_1.fastq.gz	Fastqsanger.gz
	SRR14513489_2.fastq.gz	Fastqsanger.gz
	SRR14513490_1.fastq.gz	Fastqsanger.gz
	SRR14513490_2.fastq.gz	Fastqsanger.gz
	SRR14513491_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Identification of temperature-sensitive (TS) p53 mutations and potassium antimony tartrate (PAT)-treatable p53 mutations in mammalian U937 (free of endogenous p53) cells using a systematic p53 mutation library

Project description:To identified TS p53 mutations and PAT-treatable p53 mutations in mammalian U937 cells.

2022-05-02 | GSE174348 | GEO

Transcriptome analysis of mutant p53 rescued by potassium antimony tartrate (PAT)

Project description:Transcriptome analysis of mutant p53 rescued by potassium antimony tartrate (PAT)

| PRJNA728694 | ENA

Transcriptome analysis of mutant p53 rescued by potassium antimony tartrate (PAT)

Project description:The goals of this study are to compare transcriptome of mutant p53 rescued by PAT.

2022-05-02 | GSE174185 | GEO

Single-Cell RNA-Sequencing of potassium antimony tartrate (PAT)-treated PBMCs with p53-V272M derived from an AML patient

Project description:The goals of this study are to compare transcriptome of p53-V272M rescued by PAT in primary AML PBMCs

2022-05-02 | GSE174125 | GEO

Single-Cell RNA-Sequencing of potassium antimony tartrate (PAT)-treated PBMCs with p53-V272M derived from an AML patient

Project description:Single-Cell RNA-Sequencing of potassium antimony tartrate (PAT)-treated PBMCs with p53-V272M derived from an AML patient

| PRJNA728462 | ENA

Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy

2012-07-18 | GSE39447 | GEO

Identification of arsenic trioxide (ATO)-rescuable p53 mutations and temperature-sensitive p53 mutations in p53-null U937 cells using a patient-derived 800 p53 mutation library

Project description:Thousands of diverse p53 mutations have been identified in cancer. The leukemia-treating drug arsenic trioxide (ATO) rescues a part of p53 mutations with high potency. To repurpose ATO in personalized p53-targeted therapy, here we quantitatively determined the frequent 800 p53 mutations, covering 95.8% p53 missense-mutation cases in cancer, for their rescue potencies of cell growth inhibitory activity and mouse tumor suppressive activity by ATO. Furthermore, we determined the temperature sensitivity of 800 mutations in mammalian U937 cells and founded that ATO preferentially rescued temperature-sensitive subtype of structural p53 mutants.

2024-08-01 | GSE182927 | GEO

Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy

Project description:Autism is present in 1% of the population, yet treatments are extremely limited. We identified homozygous inactivating mutations in the BCKDK gene in families presenting with autism and epilepsy. The encoded branched chain ketoacid dehydrogenase kinase protein is responsible for phosphorylation-mediated inactivation of the E1-alpha subunit of branched chain ketoacid dehydrogenase, itself mutated in Maple Syrup Urine Disease (MSUD). Patients with homozygous BCKDK mutations display reductions in BCKDK mRNA and protein, E1-alpha phosphorylation and serum branched chain amino acids (BCAAs). Bckdk knockout mice show abnormal brain amino acids profiles and neurobehavioral defects, which are largely corrected by dietary BCAA supplementation. Thus autism presenting with epilepsy due to BCKDK mutations represent a new and potentially treatable disease. A 51 chip study that includes both human and mouse samples to investigate the expression changes that result in a mutation or knockout of the BCKDK gene. Starting with human fibroblasts from three affecteds and two controls, cells were converted into IPSs, then NPCs, and finally Neurons. Each of these cell types were used to view the expression changes between a cells with a BCKDK mutation versus controls. Finally, a mouse knockout was performed to verify consistency of the expression pattern differences between the BCKCK knockout and wild-type. Samples are labeled as Affected if the sample came from a patient with a BCKDK mutation and WildType otherwise. Samples were usually replicated once.

2012-07-17 | E-GEOD-39447 | biostudies-arrayexpress

Setaria viridis strain:PAT-5 | cultivar:PAT-5

Project description:Setaria viridis strain:PAT-5 | cultivar:PAT-5 Genome sequencing

| PRJNA334531 | ENA

Identification of arsenic trioxide (ATO)-rescuable p53 mutations and temperature-sensitive p53 mutations in p53-null U937 cells using a patient-derived 800 p53 mutation library

Project description:Identification of arsenic trioxide (ATO)-rescuable p53 mutations and temperature-sensitive p53 mutations in p53-null U937 cells using a patient-derived 800 p53 mutation library

| PRJNA758368 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data